Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294574 | 0.86 | NPSR1 (0.33) | DGAT1NPC1 | |
| SCHEMBL23294459 | 0.83 | TARBP2 (0.40) | — | |
| SCHEMBL26677486 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL13598844 | 0.75 | NPC1 (0.41) | DGAT1NPC1 | |
| SCHEMBL31273849 | 0.73 | CSNK2A1 (0.40) | — | |
| SCHEMBL26849393 | 0.73 | NPC1 (0.35) | DGAT1NPC1 | |
| SCHEMBL26677622 | 0.72 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL31274451 | 0.72 | NPC1 (0.34) | NPC1 | |
| SCHEMBL26677597 | 0.71 | — | — | |
| SCHEMBL31419057 | 0.70 | DGAT1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720064-A1 | FUSED AZOLED AS TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4532485-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024246602-A1 | FUSED AZOLED AS TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023227946-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227946-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-11-30 | — | — | WO | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | DGAT1 313/4885NPC1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.